Literature DB >> 19201921

Perspectives on eGFR reporting from the interface between primary and secondary care.

Chee Kay Cheung1, Sunil Bhandari.   

Abstract

The introduction of estimated GFR (eGFR) reporting based on the Modification of Diet in Renal Disease (MDRD) equation has caused much debate regarding its value in the wider community. In particular, automated reporting of eGFR by laboratories has led to concern that it is being used as a "covert " screening tool, in populations in which the MDRD equation has known inaccuracies. There is a fear of creating a population of "worried well, " with potential impact on patients and implications for the use of resources. It is established that in certain groups, chronic kidney disease confers a greatly increased risk of cardiovascular disease, yet risk factors remain inadequately managed. We believe that eGFR reporting allows the opportunity to stratify risk and improve outcome among a wide population.

Entities:  

Mesh:

Year:  2009        PMID: 19201921     DOI: 10.2215/CJN.05151008

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  3 in total

1.  Imprecision of creatinine-based GFR estimates in uninephric kidney donors.

Authors:  Jane C Tan; Bing Ho; Stephan Busque; Kristina Blouch; Geraldine Derby; Bradley Efron; Bryan D Myers
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-28       Impact factor: 8.237

2.  Chronic kidney disease identification in a high-risk urban population: does automated eGFR reporting make a difference?

Authors:  Laura C Plantinga; Delphine S Tuot; Vanessa Grubbs; Chi-yuan Hsu; Neil R Powe
Journal:  J Urban Health       Date:  2012-12       Impact factor: 3.671

3.  Multicenter epidemiological study to assess the population of CKD patients in Greece: results from the PRESTAR study.

Authors:  Konstantinos Sombolos; Demitrios Tsakiris; John Boletis; Demetrios Vlahakos; Kostas C Siamopoulos; Vassilios Vargemezis; Pavlos Nikolaidis; Christos Iatrou; Eugene Dafnis; Konstantinos Xynos; Christos Argyropoulos
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.